Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
A key lesson for the pharmaceutical sector in this case is to not downplay the significant impact that regulatory non-compliance can have on operations.
IT major TCS worst hit; it's m-cap slumped by Rs 11,811.13 cr to Rs 4,92,042.26 cr
India seeks greater market access for its products including textiles, pharmaceuticals and bovine meat.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
In the ranking of top-10 firms, TCS stood at number one position
The FDA has been tightening its monitoring of Indian pharma majors over compliance issues. Surprise plant inspections and import alerts have been frequent outcomes
The recalled drug bottles were distributed by Caraco Pharmaceutical Laboratories, Ltd in the US while manufactured in India by Sun Pharmaceutical Industries Ltd.
The Halol facility is important for the company as it accounts for 10 per cent of Sun Pharma's sales.
The rupee recovered from more-than three months low of 63.15 in early trade on dollar selling by banks.
In March, the FDA had issued an import alert, banning formulations and active pharmaceutical ingredients from the factory.
It had posted net profit of Rs 125.75 crore (Rs 1.25 billion) during the January-March quarter of the previous fiscal, 2012-13.
Two individuals filed the petition in the high court of Andhra Pradesh
At the start of 2016, HDFC Bank, Infosys, ICICI Bank, L&T and Axis Bank were the top five picks of fund managers
The recalled drugs were manufactured and distributed in the US by Ohm Laboratories.
Rosier year-end seen for Indian pharma thanks to faster US approvals.
Company aims to build five Rs 100 cr-plus brands and launch products from South African arm in domestic market
Sun Pharma and Dr Reddy's top list in terms of those who face most class-action litigation
Who is to take their place? Will a new generation of entrepreneurs start up with better business sense, or at least better luck? But the so-called unicorns are mostly copy-cat entrepreneurs whose cash flow is funded by overseas (including Chinese) money, notes T N Ninan.
The group is looking into a new role for Ranbaxy CEO and MD Arun Sawhney.
Credit Suisse analysts cut their rating on Sun Pharma stock to 'neutral' from 'outperform
The m-cap of ONGC dipped Rs 13,303.78 crore, while that of Infosys tanked Rs 12,162.32 crore
The Hinduja Group, Mukesh Ambani, Murugappa, and the Adani groups were the other gainers in the Modi regime, while Naveen Jindal and Sun Pharma groups saw the most erosion in their m-cap in the last five years, reports Krishna Kant.
Sun Pharma open to large acquisitions post Ranbaxy.
The merger has fortified Sun Pharma's position.
Sun Pharma profit down 30% over compliance costs, lower sales.
As on July 31, the valuation of his shareholding in the company stood at Rs 9,830 crore.
Data late on Wednesday showed consumer price inflation eased more than-expected to a 25-month low of 8.10 per cent in February, while industrial output unexpectedly expanded, albeit only by 0.1 per cent.
Is yet to decide about the partnership or acquisition route
.jpg)
ITC, TCS and HDFC Bank emerged as the biggest gainers during the period.
FDA had cancelled Ranbaxy's approvals to launch generic Nexium, Valcyte
Competition watchdog says 'high market concentration' in some segments a worry.
In 2008, the 13 companies on the list accounted for 34 per cent of the overall m-cap.
The deal had separately come under scanner of the market regulator Sebi for alleged insider trading violations and the present 'no-objection' from the exchanges.
A global policy would reward firms which strive for higher quality.
Sun Pharma's Dilip Shanghvi is India's richest person.
The combined market valuation of top six Sensex companies surged by Rs 26,346 crore last week, with Reliance Industries and HDFC contributing the most to the gains.
Ranbaxy was asked to sell all products containing Leuprorelin which are marketed and supplied under brand name Eligard.
Sun Pharma's offer was tempting because Ranbaxy was too busy fighting fires in the US to concentrate on operations.
4 Ranbaxy facilities in India have been barred from exporting to US.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances